Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
National, multicenter, prospective, observational, non-interventional study. The objective is
to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated
with VKA with issues in deep venous thrombosis (DVT), and prevention of recurrent DVT and
pulmonary embolism (PE) is associated with an improvement of the treatment satisfaction after
3 months. The treatment satisfaction will be measured by the Anti Clot Treatment Scale (ACTS)
score.